13F HOLDINGS REPORT
Caligan Partners LP
Quarter ended Q2 2023 · Filed May 15, 2023 · Accession 0001814554-23-000002
Total Value
$143.4M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | LIQUIDIA CORP | LQDA | 9,243,627 | $63.9M | 44.55% |
| 2 | ANIKA THERAPEUTICS INC | ANIK | 715,291 | $20.5M | 14.33% |
| 3 | STANDARD BIOTOOLS INC | LAB | 8,576,799 | $16.7M | 11.67% |
| 4 | EXELIXIS INC | EXEL | 850,000 | $16.5M | 11.51% |
| 5 | EVOLUS INC | EOLS | 1,523,484 | $12.9M | 8.99% |
| 6 | ADMA BIOLOGICS INC | ADMA | 1,662,613 | $5.5M | 3.84% |
| 7 | VERONA PHARMA PLC | 925050106 | 183,064 | $3.7M | 2.56% |
| 8 | SOCIETAL CDMO INC | 75629F109 | 1,077,268 | $1.3M | 0.89% |
| 9 | EYEPOINT PHARMACEUTICALS INC | EYPT | 435,298 | $1.3M | 0.89% |
| 10 | ALIMERA SCIENCES INC | 016259202 | 478,777 | $1.0M | 0.70% |
| 11 | AGIOS PHARMACEUTICALS INC | AGIO | 4,333 | $99,529 | 0.07% |